Despite depletion of CD8+ T cells, ONP-302 treatment led to a statistically significant 47% reduction in tumor burden (p=0.016) (Figure 1D). In another experiment, we used immunodeficient NOD-SCIDγ (NSG) mice which lack effector immune function. This evidence concerns the gene CD8A and neoplasm.